Table 4. . Logistic regression results for association of coenzyme Q10 with the continuation of statin therapy despite a history of statin-associated muscle symptoms.

Variables	Odds ratio (95% CI)	p-value
Model 1 (unadjusted)
Coenzyme Q10 use	1.05 (0.60–1.82)	0.868

Model 2† (adjusted)
Coenzyme Q10 use	1.07 (0.61–1.89)	0.804
Hypertension	0.81 (0.55–1.18)	0.265
Obesity	1.31 (0.81–2.11)	0.277
Smoking	0.93 (0.63–1.37)	0.696
Lovastatin vs atorvastatin	0.80 (0.30–2.15)	0.851
Pravastatin vs atorvastatin	0.85 (0.41–1.77)	0.952
Rosuvastatin vs atorvastatin	1.18 (0.68–2.05)	0.232
Simvastatin vs atorvastatin	0.89 (0.55–1.44)	0.920
Other statin vs atorvastatin‡	0.60 (0.16–2.28)	0.512
Family history of heart disease	0.71 (0.48–1.03)	0.068

Model 3§ (adjusted)
Coenzyme Q10 use	1.09 (0.62–1.92)	0.761
Smoking	1.10 (0.75–1.61)	0.633
Obesity	0.81 (0.51–1.30)	0.383
Family history of muscle disease	0.64 (0.28–1.46)	0.287

Bold p-values indicate p < 0.05.

^†Adjusted for the five variables that were statistically significant in the original study for an association with SAMS [15].

^‡Other statins include cerivastatin, fluvastatin and pitavastatin.

^§Adjusted for the three variables that were significantly different between Coenzyme Q10 users and non-users in Table 1.

SAMS: Statin-associated muscle symptoms.